Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and reduces costs ...

"For me, it is a wake-up call for our country and for the African continent as a whole. We must not let the crisis pass (in ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

Colson explained that previous phase 3 trials assessing DOR and ISL as a combination using a higher daily islatravir dose (0.75 mg) showed declines in the total lymphocyte and CD4 counts ...

A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.